Immudyne, Inc. (Pink Sheets:IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, today announced the Company will present the outcome of Its clinical phase I and pivotal cancer studies at the World Immune Regulator Meeting (WIRM) at the Congress Center in Davos, Switzerland on March 18, 2012.

The special focus of the World Immune Regulation Meeting VI is on Innate and Adaptive Immune Response and Role of Tissues in Immune Regulation.

Additional recent company milestones include:

  • PFK LLP, New York, completed audited Financials for years 2009 and 2010 (clean opinion)
  • PKF LLP, New York in process of completing audited Financials for 2011
  • new corporate website: www.immudyne.com
  • re-purchased and retired 3 million options
  • upgraded OTC markets (www.otcmarkets.com) status to Fully Current
  • retirement of 1,136,842 shares in Q3/Q4

Immudyne has approximately 24 million shares outstanding. About Immudyne

Immudyne makes immune system support products:

  • all natural derived from yeast (notable the purest)
  • protected by numerous patents/proprietary trade secret know how
  • Clinical evidence
  • For pharmaceutical, nutraceutical, and topical/aesthetic dermatological
  • best in class/stable and reliable

Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.immudyne.com (currently being transformed). Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

CONTACT: Immudyne, Inc.
         Mark McLaughlin
         +1-914-714-8901
         MarkMcL@immudyne.com